The High-Affinity Interaction between ORC and DNA that Is Required for Replication Licensing Is Inhibited by...

Area of Science:

• Molecular Biology
• Cell Cycle Regulation
• Cancer Therapeutics

Background:

• DNA replication origin licensing, involving minichromosome maintenance proteins (MCM2-7), is crucial for cell cycle progression.
• A licensing checkpoint in G1 delays cells until sufficient origins are licensed; this checkpoint is often lost in cancer cells.
• Inhibiting DNA replication licensing offers a potential strategy to selectively target cancer cells.

Purpose of the Study:

• To identify novel inhibitors of DNA replication licensing.
• To characterize the mechanism of action of identified inhibitors.
• To evaluate the therapeutic potential of these inhibitors against cancer cells.

Main Methods:

• High-throughput cell-based screening to identify licensing inhibitors.
• Biochemical assays to study the interaction between origin recognition complex (ORC), DNA, and ATP.
• Allosteric inhibition studies.

Main Results:

• A new class of compounds, 2-arylquinolin-4-amines, were identified as potent inhibitors of DNA replication licensing.
• The most potent compound, RL5a, was characterized.
• RL5a inhibits the formation of a stable ORC-DNA complex, which is essential for MCM2-7 loading.
• RL5a acts allosterically, mimicking the effect of ATP depletion on ORC function.

Conclusions:

• RL5a effectively inhibits DNA replication licensing by disrupting the ORC-DNA interaction.
• The mechanism involves allosteric inhibition of ORC, mimicking ATP absence.
• RL5a represents a promising lead compound for developing novel cancer therapeutics that exploit the loss of the licensing checkpoint in cancer cells.